Femasys Inc Ordinary Shares FEMY 深 沪
已收盘 10-31 16:00:00 美东时间
0.6371
+0.016
+2.53%
华盛通- 最 高0.6436
- 今 开0.6261
- 成交量 71.91万股
- 最 低 0.603
- 昨 收 0.6214
- 总市值 2803.49万
- 52周最高 1.80
- 市盈率 静 --
- 换手率 1.63%
- 52周最低 0.3067
- 委 比 92.80%
- 总股本 4400.40万
- 历史最高 13.75
- 量 比 0.18
- 振 幅 6.53%
- 历史最低 0.2479
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
Biomedical innovator Femasys Inc. announced the commencement of a post-market surveillance (PMS) clinical study for its CE-marked FemBloc Permanent Birth Control, aligning with the European Union Medical Device Regulation (MDR 2017/745). The study, approved by multiple Ethics Committees and conducted in compliance with ISO 14155:2020, aims to monitor safety and performance in real-world settings. FemBloc, a first-of-its-kind non-surgical solution...
10-22 13:00
Femasys Meets Nasdaq Equity Requirement After Offering
Femasys ( ($FEMY) ) has issued an update. On May 19, 2025, Femasys Inc. receive...
10-21 21:48
Femasys COO Daniel Currie Announces Retirement
Femasys ( ($FEMY) ) has provided an announcement. On October 13, 2025, Daniel C...
10-18 05:50
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
Femasys Inc. will showcase its latest fertility solution, FemaSeed® Intratubal Insemination, at the ASRM 2025 Scientific Congress & Expo in San Antonio, Texas. The product, designed to enhance natural fertilization by delivering sperm to the fallopian tube, offers a safe, accessible, and cost-effective alternative to intrauterine insemination (IUI). With more than double the pregnancy rates of IUI in cases of low male sperm count, FemaSeed is aut...
10-16 13:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 46.4% to $0.37 during Tuesday...
10-15 05:06
Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) rose sharply in pre-market ...
10-06 21:01
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
<p>Femasys Inc. has partnered with Kebomed to commercialize its FemBloc permanent birth control in France and the Benelux region, leveraging Kebomed’s extensive European distribution network. FemBloc, a first-of-its-kind non-surgical solution for permanent contraception, addresses unmet needs in women’s reproductive health by eliminating risks associated with surgical sterilization. This collaboration marks a significant step in Femasys’ European...
09-25 13:00
Femasys Partners With Medical Electronic Systems To Provide Advanced Sperm Analysis Technology
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Medical
09-22 21:02
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
Femasys Inc. partners with Medical Electronic Systems LLC (MES) to offer advanced sperm analysis technology, completing the FemSperm product family. This enables gynecologists to perform in-office sperm preparation and analysis for FemaSeed Intratubal Insemination, a cost-effective infertility treatment. The collaboration enhances Femasys’ infertility portfolio and expands access to quality care.
09-22 13:00
Femasys Launches FemSperm Insemination Prep Kit To Boost Gynecologist Adoption Of FemaSeed Fertility Treatment
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduction of its FemSperm
09-11 21:05
